Fulvestrant in treatment for metastatic breast cancer
L. Yu. Vladimirova,
I. L. Popova,
N. A. Abramova,
A. E. Storozhakova,
N. M. Tikhanovskaya,
K. A. Novoselova,
A. A. L’yanova,
L. A. Ryadinskaya,
M. O. Ezhova,
M. A. Teplyakova,
L. K. Strakhov https://doi.org/10.21518/2079-701X-2019-19-58-64
Abstract
Background. Metastatic breast cancer is still an incurable disease, and is currently regarded as a chronic process requiring longterm treatment with periodic therapy replacements. Hormonal therapy shows its therapeutic efficacy with less toxicity and a better quality of life for patients compared with chemotherapy and is one of the main treatment for patients with luminal subtypes of breast cancer.
The purpose of the study was to assess the efficacy and toxicity of fulvestrant in treatment for metastatic breast cancer.
Material and methods. The study included patients with metastatic breast cancer with positive hormonal status developing progression after adjuvant treatment or chemotherapy or hormonal therapy due to metastatic cancer, ECOG≤2, with normal liver, kidney and marrow function. Fulvestrant was administered intramuscularly 500 mg once a month with a loading dose 500 mg on day 14 of the first month. The effect was evaluated every 3 months.
Results. We analyzed the efficacy and safety of fulvestrant in second-line and over treatment of 20 patients with metastatic breast cancer. Overall response was 65% (13 patients), including partial remission (PR) in 2 (10%) and stabilization in 11 (55%) patients. Progression was found in 7 (35%) patients. The median of relapse-free survival was 6 month. 1-year overall event-free survival was 45%. The median of overall survival was not reached due to the short observation period. 1-year overall survival was 70%. Adverse events in our group of patients included asthenia (80%), hot flushes (25%), headache and nausea (20%).
Conclusions. The efficacy of fulvestrant in patients with metastatic breast cancer was high enough and did not depend on the previous treatment, with a favorable toxicity profile.
The purpose of the study was to assess the efficacy and toxicity of fulvestrant in treatment for metastatic breast cancer.
Material and methods. The study included patients with metastatic breast cancer with positive hormonal status developing progression after adjuvant treatment or chemotherapy or hormonal therapy due to metastatic cancer, ECOG≤2, with normal liver, kidney and marrow function. Fulvestrant was administered intramuscularly 500 mg once a month with a loading dose 500 mg on day 14 of the first month. The effect was evaluated every 3 months.
Results. We analyzed the efficacy and safety of fulvestrant in second-line and over treatment of 20 patients with metastatic breast cancer. Overall response was 65% (13 patients), including partial remission (PR) in 2 (10%) and stabilization in 11 (55%) patients. Progression was found in 7 (35%) patients. The median of relapse-free survival was 6 month. 1-year overall event-free survival was 45%. The median of overall survival was not reached due to the short observation period. 1-year overall survival was 70%. Adverse events in our group of patients included asthenia (80%), hot flushes (25%), headache and nausea (20%).
Conclusions. The efficacy of fulvestrant in patients with metastatic breast cancer was high enough and did not depend on the previous treatment, with a favorable toxicity profile.
About the Authors
L. Yu. Vladimirova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Head of Department of Medication-Based Tumor Treatment
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
I. L. Popova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Department of Medication-Based Tumor Treatment
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
N. A. Abramova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Department of Medication-Based Tumor Treatment
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
A. E. Storozhakova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Physician, Department of Anticancer Drug Therapy No. 2
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
N. M. Tikhanovskaya
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Oncologist, Department of Anticancer Drug Therapy No. 1
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
K. A. Novoselova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Oncologist, Department of Anticancer Drug Therapy No. 1
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
A. A. L’yanova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Oncologist, Department of Anticancer Drug Therapy No. 1
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
L. A. Ryadinskaya
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Oncologist, Department of Anticancer Drug Therapy No. 1
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
M. O. Ezhova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Oncologist, Clinical Diagnostic Department
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
M. A. Teplyakova
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Oncologist, Department of Anticancer Drug Therapy No. 1
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
L. K. Strakhov
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
junior Researcher, Department of Medication-Based Tumor Treatment
63, 14-ya Liniya, Rostov-on-Don, 344037, Russia
References
1. Kramchaninov M.M. Modern ideas on the optimization of endocrine therapy of metastatic RE + / RP +, HER2-breast cancer: a review..www.medline.ru. Oncologiya = Oncology. 2017;(8). (In Russ.) Available at: http://medline.ru/public/art/tom18/art30.html.
2. Kravchenko D.N., Parokonnaya A.A., Nechushkin M.I., Avtomonov D.E. Special approaches in the hormonal treatment of breast cancer in young patients. Klinicheskaya praktika = Journal of Clinical practice. 2016;(2):15–19. (In Russ.) Available at: http://www.clinpractice.ru/upload/iblock/8ce/8cef3a1f8fe416dc983a0ffddab88467.pdf.
3. Artamonova E.V. A new drug strategy for the treatment of luminal HER2-negative metastatic breast cancer. Meditsinskiy sovet = Medical Council. 2017;(6):30–37. (In Russ.) doi: 10.21518/2079-701X-2017-6-30-37.
4. Zikiryakhodzhaev A.D., Rasskazova E.A. Modern principles for the treatment of breast cancer. Meditsinskiy alfavit=Medical alphabet. 2017;1(16). (In Russ.) Available at: https://medalphabet.elpub.ru/jour/article/view/146.
5. Ramazanova M.S., Golyakova A.V., Popov M.YU., Kislichko S.A. Hormonotherapy in the treatment of metastatic breast cancer (literature review). Vyatskiy meditsinskiy vestnik = Medical Newsletter Of Vyatka. 2018;(4):54-59. (In Russ.) Available at: https://elibrary.ru/item.asp?id=36921702.
6. Smagulova K.K., Ukolova E.A., Chichua N.A., Kurmankulova A.ZH. A clinical case for the treatment of luminal metastatic breast cancer. Onkologiya i radiologiya Kazakhstana = Oncology and radiology of Kazakhstan. 2017;(4):37–40. (In Russ.) Available at: https://elibrary.ru/item.asp?id=36470480.
7. Rugo H.S., Rumble R.B., Macrae E. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J. Clin Oncol. 2016;25(34):3069–3103. doi: 10.1200/JCO.2016.67.1487.
8. Finn R.S., Martin M., Rugo H. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;20(375):1925–1936. doi: 10.1056/NEJMoa1607303.
9. Turner N.C., Ro J., Andre F. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;3(373):209–219. doi: 10.1056/NEJMoa1505270.
10. Semiglazov V.F., Dashyan T.A., Semiglazov V.V. Breast Cancer Endocrinotherapy: Overcoming Resistance. Ehffektivnaya farmakoterapiya = Effective pharmacotherapy. 2015;(10):32-40. (In Russ.) Available at: http://umedp.ru/articles/endokrinoterapiya_raka_molochnoy_zhelezy_preodolenie_rezistentnosti.html.
11. Plavinskiy S.L., Shabalkin P.I. The use of an inhibitor of cyclin-dependent kinases 4/6 (palbotsiklib) in the treatment of hormone-dependent metastatic breast cancer. Cost-benefit analysis. Sibirskiy onkologicheskiy zhurnal = Siberian Oncology Journal. 2017;16(4):19–25. (In Russ.) doi: 10.21294/1814-4861-16-4-19-25.
12. Cristofanilli M., Turner N.C., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;4(17):425–439. doi: 10.1016/S1470-2045(15)00613-0.
13. Yardley D.A., Noguchi S., Pritchard K.I. et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;10(30):870–884. doi: 10.1007/s12325-013-0060-1.
14. Stenina M.V. The latest research on hormone therapy for advanced breast cancer. Is it time to change the paradigm of hormone therapy for breast cancer? Preconditions for differences in the effectiveness of hormone therapy drugs. Effective pharmacotherapy. 2017;(37). (In Russ.) Available at: https://elibrary.ru/download/elibrary_30488203_37921426.pdf.
15. Vladimirova L.Yu. Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer. Sovremennaya Onkologiya = Modern Oncology. 2016;18(4):23–26. (In Russ.) Available at: https://con-med.ru/magazines/contemporary/contemporary-04-2016/fulvestrant_v_endokrinnoy_terapii_retsidiviruyushchego_i_metastaticheskogo_raka_molochnoy_zhelezy.
16. Patani N., Martin L.A. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol. Cell. Endocrinol. 2014;1(382):683–694. https://doi.org/10.1016/j.mce.2013.09.038.
17. Vysotskaya I.V. Faslodex in endocrinotherapy of breast cancer. Effective pharmacotherapy. 2011;(22):18-21. (In Russ.) Available at: https://cyberleninka.ru/article/v/sovremennye-vozmozhnosti-endokrinoterapii-raka-molochnoy-zhelezy.
18. Semiglazova T.Yu. The latest research on hormone therapy for advanced breast cancer. Is it time to revise the standards? Past and present hormone therapy for advanced breast cancer. Ehffektivnaya farmakoterapiya = Effective pharmacotherapy. 2017;(37):26-32. (In Russ.) Available at: https://elibrary.ru/item.asp?id=30488203..
19. Toy W., Shen Y., Won H. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;12(45):1439–1445. doi: 10.1038/ng.2822.
20. Osborne C.K., Wakeling A., Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;(90)1:S2–S6. doi: 10.1038/sj.bjc.6601629.
21. Di Leo A., Jerusalem G., Petruzelka L. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;(28):4594–600. See accompanying editorial. doi: 10.1200/JCO.2010.30.6266.
22. Konstantinova M.M.,Gutorov S.L., Trishkina E.A, Statsenko G.B., Koroleva I.A., Kuz’mina E.S., Belonogov A.V., Sheveleva L.P., Ehfendiev V. The modes of the second endocrine therapy in patients with advanced breast cancer and their impact on the quality of life (according to the Russian multicenter prospective cohort observational study LINE). Zlokachestvennye opukholi = Malignant tumors. 2017;3(7):75-76. (In Russ.) Available at: https://elibrary.ru/item.asp?id=32329758.
23. Di Leo A., Jerusalem G., Petruzelka L. et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;(106):djt337. doi: 10.1093/jnci/djt337.
24. Krasil’nikova S.yu.,Petkau V.V. Experience with the use of the drug fulvestrant (phaslodex) in the treatment of metastatic breast cancer. Ural’skiy meditsinskiy zhurnal = Ural Medical Journal. 2015;7(130):48-50. (In Russ.) Available at: https://elibrary.ru/item.asp?id=24313371.
25. Robertson J.F., Llombart-Cussac A., Rolski J. et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin. Oncol. 2009;27(27):4530–4535. doi: 10.1200/JCO.2008.21.1136.
26. Ingle J.N., Suman V.J., Rowland K.M. et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006;(24):1052–1056. Available at: https://ascopubs.org/doi/full/10.1200/JCO.2005.04.1053?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed.
27. Chia S., Gradishar W., Mauriac L. et al. Doubleblind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;(26):1664–1670. doi: 10.1200/JCO.2007.13.5822.
28. Telford et al. A network meta-analysis of fulvestrant vs alternative first-line endocrine therapies for endocrine therapy-naïve postmenopausal hormone receptor-positive advanced or metastatic breast cancer. Journal of Clinical Oncology. 2017;35(15_suppl):e12545-e12545. doi: 10.1200/JCO.2017.35.15_suppl.e12545.
29. Robertson J.F., Bondarenko I.M., Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, doubleblind, phase 3 trial. Lancet. 2017;388(10063): 2997–3005. doi: 10.1016/S0140-6736(16)32389-3.
Review
For citations:
Vladimirova LY, Popova IL, Abramova NA, Storozhakova AE, Tikhanovskaya NM, Novoselova KA, L’yanova AA, Ryadinskaya LA, Ezhova MO, Teplyakova MA, Strakhov LK. Fulvestrant in treatment for metastatic breast cancer. Meditsinskiy sovet = Medical Council. 2019;(19):58-64. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-58-64
Views:
2130
Email this article 